Pathotropic targeting advances clinical oncology: Tumor-targeted localization of therapeutic gene delivery | Zendy

⁄ Gordon | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pathotropic targeting advances clinical oncology: Tumor-targeted localization of therapeutic gene delivery

Author(s) -

⁄ Gordon

Publication year - 2010

Publication title -

oncology reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.094

H-Index - 96

eISSN - 1791-2431

pISSN - 1021-335X

DOI - 10.3892/or.2010.829

Subject(s) - molecular medicine , oncogene , cancer research , cancer , cell cycle , precision medicine , medicine , targeted therapy , disease , biology , oncology , bioinformatics , pathology

The advent of pathotropic (disease-seeking) targeting has transported genetic medicine across the threshold of history with the progressive clinical validation of Rexin-G, a tumor-targeted nanosized anti-cancer agent. Achieving noteworthy single-agent efficacy and survival benefits in otherwise intractable cancers, the molecular biotechnology platform has stimulated intense interest in the underlying mechanisms-of-action. This report exhibits the effective localization of Rexin-G nanoparticles within a metastatic liver lesion, as observed upon its surgical excision.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research